X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (257) 257
female (199) 199
male (199) 199
middle aged (172) 172
index medicus (152) 152
aged (150) 150
cardiac & cardiovascular systems (123) 123
heart failure (97) 97
mortality (89) 89
prognosis (71) 71
adult (66) 66
risk factors (60) 60
aged, 80 and over (53) 53
myocardial infarction (49) 49
risk (46) 46
abridged index medicus (45) 45
atrial fibrillation (45) 45
double-blind method (44) 44
prospective studies (44) 44
cardiovascular (41) 41
hypertension (41) 41
medicine, general & internal (41) 41
patients (40) 40
stroke (40) 40
drug therapy (39) 39
heart attacks (37) 37
cardiovascular disease (36) 36
management (34) 34
treatment outcome (34) 34
acute heart failure (32) 32
analysis (32) 32
acute coronary syndromes (31) 31
follow-up studies (30) 30
prevention (30) 30
cardiology (29) 29
care and treatment (29) 29
heart failure - mortality (29) 29
diagnosis (28) 28
hospitalization (28) 28
outcomes (28) 28
cardiovascular diseases (27) 27
diabetes (26) 26
guidelines (26) 26
therapy (26) 26
patient outcomes (25) 25
acute disease (24) 24
blood pressure (24) 24
heart failure - drug therapy (24) 24
acute coronary syndrome (23) 23
association (23) 23
electrocardiography (23) 23
internal medicine (23) 23
warfarin (23) 23
cardiac patients (22) 22
cardiology and cardiovascular medicine (22) 22
hemorrhage - chemically induced (22) 22
heart diseases (21) 21
heart failure - diagnosis (21) 21
anticoagulants (20) 20
chronic heart failure (20) 20
heart attack (20) 20
myocardial-infarction (20) 20
research (20) 20
secondary prevention (20) 20
hemorrhage (19) 19
medicine (19) 19
stroke - prevention & control (19) 19
survival (19) 19
trial (19) 19
acute myocardial-infarction (18) 18
aspirin (18) 18
cardiogenic shock (18) 18
heart rate (18) 18
hypertension - drug therapy (18) 18
life sciences (18) 18
myocardial infarction - drug therapy (18) 18
time factors (18) 18
biomarkers - blood (17) 17
heart failure - blood (17) 17
heart failure - physiopathology (17) 17
kaplan-meier estimate (17) 17
medical research (17) 17
platelet aggregation inhibitors - therapeutic use (17) 17
prevalence (17) 17
coronary vessels (16) 16
disease (16) 16
dosage and administration (16) 16
drug therapy, combination (16) 16
heart-failure (16) 16
ischemia (16) 16
risk assessment (16) 16
cardiovascular diseases - mortality (15) 15
health risk assessment (15) 15
hospital mortality (15) 15
peripheral vascular disease (15) 15
adolescent (14) 14
angiotensin-converting enzyme inhibitors - therapeutic use (14) 14
coronary artery disease (14) 14
death (14) 14
heart (14) 14
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10055, pp. 1995 - 2003
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2012, Volume 366, Issue 15, pp. 1404 - 1413
Patients with atherosclerotic vascular disease were randomly assigned to receive the thrombin antagonist vorapaxar or placebo. Vorapaxar reduced the rate of... 
ATOPAXAR | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | EFFICACY | SAFETY | TOLERABILITY | DOUBLE-BLIND | PRASUGREL | LESSONS | ANTAGONISTS | ASPIRIN | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Risk | Secondary Prevention | Pyridines - adverse effects | Cardiovascular Diseases - mortality | Female | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Pyridines - therapeutic use | Double-Blind Method | Hemorrhage - epidemiology | Receptor, PAR-1 - antagonists & inhibitors | Kaplan-Meier Estimate | Peripheral Arterial Disease - drug therapy | Stroke - drug therapy | Lactones - adverse effects | Lactones - therapeutic use | Retreatment | Myocardial Infarction - drug therapy | Brain Ischemia - drug therapy | Intracranial Hemorrhages - chemically induced | Intracranial Hemorrhages - epidemiology | Aged | Hemorrhage - chemically induced | Prevention | Drugs | Aggregation | Dose-response relationship (Biochemistry) | Atheroembolism | Blood platelets | Atherosclerosis | Product/Service Evaluations | Dosage and administration | Drug therapy | Myocardial infarction | Cerebral infarction | Stroke | Aspirin | Heart attacks | Proteinase-activated receptor 1 | Thrombin | Hemorrhage | Patients | Bleeding | Disease prevention | Ischemia | Arteriosclerosis | Death | Cardiovascular diseases | Health risk assessment | Computer Science | Medical Imaging
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Life Sciences | Human health and pathology
Journal Article